AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7792126
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil (8 mg/kg/day twice daily)
Trial: 31255371
Drug: Nutritional counseling
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional counseling plus a low-cost, intradialytic, protein-rich meal (200 mL milk plus two egg whites) thrice weekly for 3 months.
Trial: 31074184
Drug: Acetazolamide 250–500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250–500 mg daily plus bumetanide 1–2 mg bid
Trial: 31074184
Drug: High-dose loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose loop diuretics (bumetanide bid with daily dose twice the oral maintenance dose)
Trial: 23286595
Drug: Proactive telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive telephone counseling with tailored self‐directed materials (including nicotine patches, if not contraindicated)
Trial: 23286595
Drug: Tailored self‐directed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored self‐directed materials (including nicotine patches, if not contraindicated)
Trial: 21585706
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + cisplatin-based chemotherapy
Trial: 17028377
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg zinc daily for 4 weeks
Trial: 9438895
Drug: Granisetron 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 3.0 mg
Trial: 1976664
Drug: Cetirizine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine, 20 mg/day for 4 days
Trial: 416195
Drug: Peripheral total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral total parenteral nutrition (TPN) consisting of casein hydrosylate, dextrose, and soybean emulsion
Trial: 31558398
Drug: Intravenous thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous thiamine (600 mg on the day of surgery, and 400 mg/day on postoperative days 1, 2, and 3)
Trial: 12478408
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1 g t.i.d.)
Trial: 22584353
Drug: Preemptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive therapy with valganciclovir (900 mg b.i.d. for a minimum of 14 days)
Trial: 22584353
Drug: Deferred therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred therapy
Trial: 18030070
Drug: Usual drug
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual drug therapy
Trial: 23830530
Drug: Subcutaneous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous fentanyl
Trial: 1710631
Drug: Histamine hydrochloride
RxNorm normalized name: Histamine hydrochloride
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine hydrochloride (10 and 100 mg/ml)
Trial: 1710631
Drug: Substance P
RxNorm normalized name: Substance P
DrugBank: Substance P (DB19198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance P (50 and 500 ng per injection site)
Trial: 1710631
Drug: Phentolamine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (20 micrograms per injection site)
Trial: 1710631
Drug: Carbachol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbachol (1 microgram per injection site)
Trial: 31609865
Drug: Single 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 12.5 mg naltrexone oral dose (SI group)
Trial: 31609865
Drug: Escalating dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dosage regimen starting from 50 μg up to a cumulative dose of 12.5 mg (ED group)
Trial: 28444488
Drug: Prophylactic swallowing
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic swallowing exercises, completed twice daily
Trial: 26837474
Drug: Selumetinib (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (75 mg twice daily) plus Docetaxel (75 mg/m2, intravenously on day 1 of every 21-day cycle)
Trial: 26837474
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus Docetaxel (75 mg/m2, intravenously on day 1 of every 21-day cycle)
Trial: 24638003
Drug: Imatinib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (1 year of adjuvant therapy)
Trial: 22431864
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg plus fenofibrate 200 mg
Trial: 22431864
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg plus omega-3 fatty acids 2 g
Trial: 20707696
Drug: Combination peer-educator
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination peer-educator and manager-training intervention
Trial: 16277693
Drug: Pyridoxine supplementation
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine supplementation (50 mg daily for 30 days)
Trial: 12126938
Drug: Pirfenidone (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone (800 mg, t.i.d.)
Trial: 7784126
Drug: SPf66 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPf66 vaccine adjuvanted with alum
Trial: 1316066
Drug: Lomefloxacin 400
RxNorm normalized name: lomefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin 400 mg oral dose
Trial: 1316066
Drug: Lomefloxacin up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin up to 800 mg and multiple doses up to 600 mg twice daily (1,200 mg/day)
Trial: 1316066
Drug: Lomefloxacin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin (all dosage regimens)
Trial: 29396020
Drug: Low-intensity shockwave
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity shockwave therapy sessions once per week for 6 weeks (group A)
Trial: 29396020
Drug: Low-intensity shockwave
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity shockwave therapy sessions twice per week for 6 weeks (group B)
Trial: 29396020
Drug: Repeat treatment
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat treatment after 6 months (group A received 2 sessions per week, group B received 1 session per week)
Trial: 10446869
Drug: Minocycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (100 mg twice daily)
Trial: 23980091
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg per day for 2 years
Trial: 18339031
Drug: Salbutamol (PC(20)
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol (PC(20) = 10.79 mg/L, PC(35) = 8.55 mg/L)
Trial: 18339031
Drug: Normal controls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal controls (PC(20) = 237.68 mg/L, PC(35) = 88.72 mg/L)
Trial: 12674152
Drug: Antibiotic misuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic misuse in the community
Trial: 12674152
Drug: Factors affecting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors affecting patient compliance to therapy
Trial: 9386685
Drug: Preoperative intraaortic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative intraaortic balloon pump (IABP) treatment
Trial: 7957346
Drug: Dexamethasone intervention
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone intervention (10 mg in 24 h)
Trial: 7957346
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 20 mCi (740 MBq) of technetium‐99m methylene diphosphonate (99mTc‐MDP)
Trial: 3591298
Drug: F1 (1.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F1 (1.9 g of protein and 72 kcal per 100 ml)
Trial: 3591298
Drug: F2 (2.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F2 (2.7 g of protein and 69 kcal per 100 ml)
Trial: 3591298
Drug: HM (0.96
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM (0.96 g of protein and 65 kcal per 100 ml)
Trial: 29687303
Drug: Guava leaf
RxNorm normalized name: guava leaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guava leaf extract (1 g daily)
Trial: 20048227
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy guided self-help (CBTgsh)
Trial: 20048227
Drug: Behavioral weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral weight loss treatment (BWL)
Trial: 16156881
Drug: Ritonavir 100
RxNorm normalized name: ritonavir 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir 100 mg twice-daily added to nelfinavir 1250 mg twice-daily regimen
Trial: 16156881
Drug: Nelfinavir 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir 1250 mg twice-daily regimen without ritonavir
Trial: 8017414
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin through PVC administration set
Trial: 8017414
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin through polyethylene administration set
Trial: 31169407
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA) with Propofol
Trial: 28771503
Drug: Narrowband UVB
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Narrowband UVB treatment
Trial: 26084281
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance exercise program, performed twice a week for 15 weeks
Trial: 21804375
Drug: Esomeprazole/amoxicillin/levofloxacin (EAL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole/amoxicillin/levofloxacin (EAL) - 40 mg esomeprazole twice daily, 1 g amoxicillin twice daily and 500 mg levofloxacin once daily for 7 days
Trial: 21804375
Drug: Esomeprazole/amoxicillin/metronidazole (EAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole/amoxicillin/metronidazole (EAM) - 40 mg esomeprazole twice daily, 1 g amoxicillin twice daily and 250 mg metronidazole 4 times daily for 14 days
Trial: 17042884
Drug: Quetiapine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine monotherapy (up to 800 mg/day)
Trial: 17042884
Drug: Quetiapine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine + Lithium/Divalproex (up to 800 mg/day)
Trial: 17042884
Drug: Haloperidol monotherapy
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol monotherapy
Trial: 8985623
Drug: Ephedrine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (50 mg)
Trial: 10209349
Drug: Sumatriptan nasal
RxNorm normalized name: SUMAtriptan nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan nasal spray 5 mg
Trial: 10227648
Drug: Sumatriptan nasal
RxNorm normalized name: SUMAtriptan nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan nasal spray
Trial: 7696164
Drug: AVP induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVP induction chemotherapy (adriamycin, etoposide, cisplatin given every four weeks for four cycles)
Trial: 7696164
Drug: EVA induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVA induction chemotherapy (cyclophosphamide, etoposide, adriamycin given every four weeks for four cycles)
Trial: 7696164
Drug: MOC/AVP induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOC/AVP induction chemotherapy (methotrexate, vincristine, cyclophosphamide alternating with adriamycin, etoposide, cisplatin for two cycles)
Trial: 7696164
Drug: Combined-modality maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-modality maintenance therapy (radiation therapy to the chest followed by MOC/EVA chemotherapy)
Trial: 7696164
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy alone (without consolidating chest irradiation)
Trial: 2622586
Drug: Carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnitine (2 g infusion with phleboclysis)
Trial: 2622586
Drug: Tocolytics per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocolytics per os (oral)
Trial: 981
Drug: 11.2% mafenide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.2% mafenide acetate cream
Trial: 981
Drug: 5% mafenide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% mafenide acetate cream
Trial: 981
Drug: Carrier cream
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrier cream without glycerol
Trial: 25867274
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) after breast conservation therapy (BCT)
Trial: 23786655
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine (NE) 5 to 15 μg/min
Trial: 19287305
Drug: multiple hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple hepatic arterial injections of Ad‐p53 (1x10 viral particles) and 5‐FU (500‐750 mg), after TACE
Trial: 17885005
Drug: Soymilk (28.51
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soymilk (28.51 mg isoflavone aglycone equivalents/portion)
Trial: 17885005
Drug: Soy germ
RxNorm normalized name: soy germ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy germ (37.99 mg isoflavone aglycone equivalents/portion)
Trial: 8034812
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (16 sessions)
Trial: 2564458
Drug: Long-term interferon
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term interferon therapy
Trial: 2564458
Drug: Resumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resumption of interferon therapy
Trial: 28571727
Drug: Mentha pulegium
RxNorm normalized name: MENTHA PULEGIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentha pulegium extract (330mg three times daily for 2 months)
Trial: 22303583
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg kg‐1 nettle extract, three portions a day for 8 weeks
Trial: 16409198
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (latex immunotherapy)
Trial: 12654431
Drug: Conventional RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional RT and adjuvant chemotherapy
Trial: 12654431
Drug: Conventional RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional RT plus concurrent chemotherapy
Trial: 12654431
Drug: Conventional RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional RT plus concurrent chemotherapy and adjuvant chemotherapy
Trial: 11140556
Drug: Adjunctive systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive systemic doxycycline (200 mg the 1st day, then 100 mg per day for 21 days)
Trial: 1441695
Drug: Pimobendan 5
RxNorm normalized name: pimobendan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan 5 mg bid
Trial: 3548207
Drug: Piroxicam 40
RxNorm normalized name: piroxicam 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg/day for two days followed by 20 mg/day
Trial: 3548207
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid 500 mg t.i.d.
Trial: 3548207
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg b.i.d.
Trial: 30486723
Drug: Radial Extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) - 3,000 pulses each; pressure: 1.8‐2.0 bar; frequency: 10 Hz, once a week for 8 weeks.
Trial: 30486723
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of an α‐blocker and an anti‐inflammatory agent, treated for 8 weeks.
Trial: 24762108
Drug: TAK-448 (0.01-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-448 (0.01-6 mg/d; single-bolus or 2-hour infusion)
Trial: 24762108
Drug: TAK-448 (0.01-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-448 (0.01-1 mg/d; 14-day sc administration)
Trial: 24762108
Drug: TAK-448 (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-448 (12 or 24 mg sc-depot injections)
Trial: 24762108
Drug: TAK-448 (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-448 (24 mg sc-depot injections)
Trial: 1404679
Drug: 650 mg
RxNorm normalized name: bran 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg aspirin twice daily
Trial: 17208597
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg aspirin twice daily
Trial: 8869876
Drug: Oestrogen replacement
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen replacement therapy
Trial: 8582195
Drug: Combined or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined or opposed hormone replacement therapy (HRT)
Trial: 28346568
Drug: 3-monthly oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-monthly oral doses of 3 mg calcifediol plus daily exercise
Trial: 21823415
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Back‐shu point needling and trunk exercise
Trial: 19243724
Drug: Manual lymph
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual lymph drainage therapy (MLDT)
Trial: 10515308
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg d-amphetamine (low-dose group)
Trial: 10515308
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg d-amphetamine (high-dose group)
Trial: 7733124
Drug: Cyclical etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclical etidronate (400 mg/d for the first month; thereafter, 400 mg/d for 2 weeks of every 3-month period), elemental calcium (1 g/d), and ergocalciferol (0.5 mg/wk)
Trial: 7733124
Drug: Calcium supplements
RxNorm normalized name: CALCIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplements only (1 g/d)
Trial: 9481597
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg sibutramine
Trial: 1914367
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sibutramine
Trial: 7017991
Drug: 750 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/day of chenodeoxycholic acid (CDCA) for 4 months, followed by an additional 4 months for those showing a 25% or more decrease in stone size.
Trial: 31912632
Drug: Alirocumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (150 mg, subcutaneous, biweekly for 6 weeks)
Trial: 28382813
Drug: Aquatic physical
RxNorm normalized name: Mentha aquatica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic physical training (APT) program, held twice a week for 16 weeks
Trial: 25500940
Drug: Anaesthetist-directed fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthetist-directed fluid therapy
Trial: 11921054
Drug: Interferon beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1a (30 microg weekly intramuscular injections)
Trial: 2644335
Drug: Fluoxetine (ProzacR,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (ProzacR, Lilly) for 8 weeks
Trial: 23533318
Drug: Isoniazid (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid (36 months daily)
Trial: 21831926
Drug: Stay active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stay active care, muscle stretching and manual therapy (group 3)